Intercept Pharmaceuticals, Inc. (ICPT) Earns Outperform Rating from Robert W. Baird

Robert W. Baird reissued their outperform rating on shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) in a report released on Wednesday morning. They currently have a $332.00 price objective on the biopharmaceutical company’s stock.

Several other equities research analysts have also weighed in on the company. Jefferies Group LLC initiated coverage on Intercept Pharmaceuticals in a research note on Monday, July 10th. They set a buy rating and a $275.00 price objective for the company. Zacks Investment Research upgraded Intercept Pharmaceuticals from a hold rating to a buy rating and set a $136.00 target price for the company in a report on Tuesday, July 11th. Cowen and Company restated a buy rating on shares of Intercept Pharmaceuticals in a report on Monday, June 12th. ValuEngine upgraded Intercept Pharmaceuticals from a sell rating to a hold rating in a report on Friday, September 1st. Finally, BidaskClub upgraded Intercept Pharmaceuticals from a hold rating to a buy rating in a report on Thursday, July 13th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $207.75.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 8.55% during midday trading on Wednesday, hitting $94.88. The stock had a trading volume of 2,588,272 shares. The company’s 50-day moving average price is $108.47 and its 200-day moving average price is $116.36. Intercept Pharmaceuticals has a 12-month low of $85.88 and a 12-month high of $172.95. The firm’s market cap is $2.38 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, topping the consensus estimate of ($3.62) by $0.16. The business had revenue of $30.89 million during the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The company’s revenue was up 459.6% compared to the same quarter last year. During the same period last year, the company posted ($3.14) EPS. Equities research analysts forecast that Intercept Pharmaceuticals will post ($14.06) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://ledgergazette.com/2017/09/16/intercept-pharmaceuticals-inc-icpt-earns-outperform-rating-from-robert-w-baird.html.

In other Intercept Pharmaceuticals news, Director Daniel G. Welch sold 602 shares of the stock in a transaction on Monday, July 31st. The shares were sold at an average price of $123.93, for a total transaction of $74,605.86. Following the transaction, the director now directly owns 3,108 shares of the company’s stock, valued at $385,174.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel G. Welch sold 217 shares of the stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $126.76, for a total transaction of $27,506.92. Following the transaction, the director now directly owns 3,710 shares in the company, valued at $470,279.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 48,013 shares of company stock valued at $6,198,747. 9.20% of the stock is owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of the business. FMR LLC increased its position in Intercept Pharmaceuticals by 0.7% during the second quarter. FMR LLC now owns 3,750,678 shares of the biopharmaceutical company’s stock worth $454,094,000 after buying an additional 25,958 shares during the last quarter. Carmignac Gestion increased its position in Intercept Pharmaceuticals by 0.4% during the second quarter. Carmignac Gestion now owns 2,035,592 shares of the biopharmaceutical company’s stock worth $246,449,000 after buying an additional 7,400 shares during the last quarter. Vanguard Group Inc. increased its position in Intercept Pharmaceuticals by 4.5% during the second quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock worth $160,797,000 after buying an additional 57,149 shares during the last quarter. State Street Corp increased its position in Intercept Pharmaceuticals by 7.3% during the first quarter. State Street Corp now owns 805,550 shares of the biopharmaceutical company’s stock worth $91,110,000 after buying an additional 54,523 shares during the last quarter. Finally, First Trust Advisors LP increased its position in Intercept Pharmaceuticals by 17.0% during the second quarter. First Trust Advisors LP now owns 287,411 shares of the biopharmaceutical company’s stock worth $34,797,000 after buying an additional 41,856 shares during the last quarter. 82.19% of the stock is currently owned by hedge funds and other institutional investors.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply